<DOC>
	<DOCNO>NCT02908282</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy REMOGEN® OMEGA reduce Dry Eye Syndrome ( DES ) symptom .</brief_summary>
	<brief_title>Topical Omega-3 Fatty Acids ( REMOGEN® OMEGA ) Treatment Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Povidone</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male female patient 18 80 year age good general health condition . Signed write informed consent . Existence moderate severe DES symptom define Breakup time ( TBUT ) ≤ 10 ( mean 3 consecutive measurement ) OSDI questionnaire ≥ 20 . Contraindication use product ( e.g . hypersensitivity constituent test product ) study procedure . Concomitant previous participation clinical investigation within last 3 month . Concomitant therapies/manipulations affect either tear film , tear secretion ocular surface integrity would alter effect device evaluate . Concurrent ( systemic ) DESassociated disease stable therapy since least 1 month ( therapy expect change ) Glaucoma stable dosage since least 2 week ( therapy expect change ) Any disease characteristic judge investigator incompatible assessment and/or procedure study evaluation Pregnant lactating female . Participants childbearing age use adequate method birth control . Subjects unable understand inform consent high probability noncompliance study procedure and/or noncompletion study accord investigator 's judgment ( e.g . illiteracy , insufficient knowledge local language ) . Subjects capable contract understanding nature , risk , significance implication clinical investigation unable form rational intention light fact .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>tear film</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>eye drop</keyword>
</DOC>